Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma
- Donn M. Stewart(corresponding author),
- Roshan Ramanathan,
- Siddhartha Mahanty,
- Daniel P. Fedorko,
- John Edward Janik,
- John C. Morris
- National Institutes of Health,
Open access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
A 55-year-old woman with human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia (ATL) and a history of previously treated Strongyloides stercoralis infection received anti-CD52 monoclonal antibody therapy with alemtuzumab on a clinical trial. After an initial response, she developed ocular involvement by ATL. Alemtuzumab was stopped and high-dose corticosteroid therapy was started to palliate her ocular symptoms. Ten days later, the patient developed diarrhea, vomiting, fever, cough, skin rash, and a deteriorating mental status. She was diagnosed with disseminated S. stercoralis. Corticosteroids were discontinued and the patient received anthelmintic therapy with ivermectin and albendazole with complete clinical recovery.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 63-67 (5 pages)Journal (Volume, Issue Number)
Acta Haematologica (Volume 126, Issue 2)Publication milestones
- Published - 08/2011
Publication status
ISSN
0001-5792Publication IDs
- Scopus: 79953674826
- PubMed: 21474923
